Learn more about NECI’s role in Lonza Biologics Plant Expansion in this article from
The partnership will provide pharmaceutical manufacturers with “on-demand” manufacturing capability that will transform the way small-molecule pharmaceuticals are developed, manufactured, and delivered to patients.
Mansfield, MA (November 6, 2014): NECI announced a new partnership agreement with CONTINUUS Pharmaceuticals, a revolutionary spin-out company from the Massachusetts Institute of Technology (MIT). This agreement will create a path for CONTINUUS to bring their Integrated Continuous Manufacturing (ICM) process to the life sciences marketplace using Emerson’s DeltaV™ distributed control system and Syncade™ manufacturing execution system (MES).
The DeltaV system controls each step of the ICM process, while Syncade provides work process instructions to the operator so that necessary actions are completed correctly and at the right time. By implementing the innovative CONTINUUS technology, pharmaceutical manufacturers can eliminate step-by-step requirements of a traditional batch process. Instead, they can apply an integrated, continuous manufacturing methodology that simplifies the path from raw materials used in the synthesis of the active ingredient to the final dosage form. Pharmaceutical manufacturers can produce medicines at significantly reduced costs (50% reduction), with reduced lead times (90% reduction from industry standard), all while improving quality.
“CONTINUUS Pharmaceuticals’ breakthrough ICM technology for the life science industry is positioned to be a catalyst for change in an industry which operates exclusively in a batch environment,” said Mark Genest, senior account manager with NECI. “This technology will have a positive impact in both time to market and cost of manufacturing for those companies using it.”
“We have undertaken the most revolutionary approach to continuous manufacturing, where a set of new process technologies runs simultaneously, under fully automated control, from the beginning to the end of the process. This requires complex automation and an integrated control strategy of our plants. The partnership with NECI will provide us with advanced and flexible control architecture for our processes, and we are very excited about our collaboration,” said Salvatore Mascia, Founder and CEO of CONTINUUS Pharmaceuticals.
“NECI is excited to partner with CONTINUUS Pharmaceuticals. The DeltaV system and Syncade MES will be engineered to enable the rapid deployment of the ICM process providing significant ‘on-demand’ manufacturing advantages to their customers,” said Tom Ramundo, President of NECI.
CONTINUUS will initially utilize the Guest Center at NECI’ headquarters in Mansfield, Massachusetts to provide a location for customer demonstrations of the ICM process via a DeltaV simulation system. In the future, a full-scale DeltaV development system is planned to be installed in CONTINUUS’ pilot plant in Woburn, Massachusetts.
NECI delivers a broad scope of products along with the engineering, training, maintenance and asset reliability services required to solve process control needs. As a Local Business Partner of Emerson, NECI serves the life sciences, power generation, pulp & paper, gas distribution & transmission, water & wastewater and various other industries.
Learn more at: www.NECI.com
Emerson (www.Emerson.com) is a leader in helping businesses automate their production, processing and distribution in the chemical, oil and gas, refining, pulp and paper, power, water and wastewater treatment, mining and metals, food and beverage, life sciences and other industries. The company combines superior products and technology with industry-specific engineering, consulting, project management and maintenance services. Its brands include PlantWeb™, Syncade™, DeltaV™, Fisher®, Bettis™, Micro Motion®, Rosemount®, Daniel™, Ovation™ and AMS Suite.
About CONTINUUS Pharmaceuticals
CONTINUUS Pharmaceuticals is a spin-out company of the $65 million collaboration between MIT and Novartis on continuous manufacturing. CONTINUUS designs and develops integrated continuous manufacturing processes for pharmaceutical clients, providing them with an exceptional, “one-shop solution” for the entire development and manufacturing cycle.
Learn more at: http://continuuspharma.com
Beamex MC6 calibrators with Emerson’s AMS Device Manager make calibrations seamless and easy for NECI
NECI finds Emerson’s AMS Device Manager Calibration Assistant SNAP-ON combined with the Beamex MC6 calibrator and communicator an ideal calibration system for several reasons:
- Easy to use and train less experienced technicians
- Doubles the amount of work they can complete in a day with the utmost accuracy
- Ability to execute a wide variety of calibrations with agility using one device
- Reduces the amount of equipment required to maintain and carry in the field
- Saves time of manually populating or adjusting vital data
As a long-time Beamex customer, NECI has used Beamex MC5 calibrators integrated with Emerson’s AMS Device Manager via the Calibration Assistant SNAP-ON application to perform and document their work for many years. Today, they benefit from the advanced functionality of the latest Beamex MC6 calibrator. Additionally, they can take advantage of the new communication option between AMS and the MC6, which Emerson and Beamex recently released.
Biogen virtualized the infrastructure of an existing pharmaceutical manufacturing facility when converting legacy DCS to Emerson DeltaV and Syncade MES solution
See article on Controlglobal.com to learn more.
Virtualized Infrastructure Takes Hold in Pharma Process Automation
May 02, 2015
Volume 39, Issue 5
Virtualization has been mainstream in information technology (IT) for decades. One of IT’s biggest challenges is “infrastructure crawl,” caused by servers that, by design, run one operating system and one application at a time, requiring many servers to meet the needs of complex organizations. These single-application servers typically use only a fraction of what the physical server can provide, wasting computing resources across the organization.
Virtualization, however, operates on the principal that more than one operating system and application can utilize the same physical hardware or server host. This approach reduces the physical, power, and cooling footprint required to run an application.
In a traditional computer infrastructure, each physical machine has one operating system running one or more applications and requires labor and expertise to install, maintain, and upgrade. Validation and qualification efforts increase the cost burden. Upgrades in single-server application relationships increase unplanned downtimes.
Virtualized environments offer multiple virtual machine (VM) servers running on a single hardware server simultaneously. A hypervisor, computer software and firmware, runs VMs while managing physical resources on the host (central processing unit, memory, and network resource). VM host servers maximize resource utilization, because resources are handled and scheduled through the hypervisor.
It’s great that Tim Alosi, from Emerson local business partner, New England Controls, was in town this past week. He saw the recent post, Shrinking Batch Record Creation Time and Document Management Complexity. Repligen is one of New England Controls customers, and Tim had more to share on this story.